Bastide Le Confort Medical Sa · EURONEXT:BLC
Bastide Le Confort Medical Sa — 9M 2022-2023 Earnings Presentation
16 slides from Bastide Le Confort Medical Sa's earnings presentation, May 10, 2023
Slide 1: 9-month revenue 2022-2023
2022-2023 9-month revenue May 2023
Slide 2: Europe's multi-specialist in home healthcare services
Europe's multi-specialist in home healthcare services Homecare Home medical assistance In stores & Respiratory care Online Sale and lease of medical Respiratory care (oxygen therapy, 24% devices directly, in-store ventilation, sleep apnea) 32% Home (B2C) or to healthcare Nutrition – Perfusion Homeca
Slide 3: Solid long-term growth
Solid long-term growth > 510 468,3 AAGR revenue up 14% 444,1 > 42 38,9 TCMA ROC +18% 382,7 37,0 335,7 32,8 289,1 28,4 23,3 218,1 191,9 171,2 152,1 16,1 133,6 14,0 12,7 10,5 8,5 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023E Revenue in €m Recurring operating profit in €m 3
Slide 4: 9-month revenue 2022-2023
2022-2023 9-month revenue 4
Slide 5: Active external growth strategy targeting international markets and focusing on highly technical activities
Active external growth strategy targeting international markets and focusing on highly technical activities Consolidation date: July 1, 2022 Oxystore Oxygen therapy, sleep apnea, 9M 22-23 scope effect: €2.9m non-invasive ventilation RESPIRATORY Oxygen therapy, sleep apnea, non- Consolidation date: O
Slide 6: Excellent performance in Q3 2022-2023
Excellent performance in Q3 2022-2023 In € millions Q3 Q3 Change Organic Organic growth accelerates to 9.1% 2021-2022 2022-2023 growth Revenue 118.5 130.6 +10.3% +9.1% Return to organic growth in Homecare Restated revenue* • Negative 4.4% impact of PPE on growth 115.8 130.6 +12.8% +9.1% • Good momen
Slide 7: Sustained organic growth throughout the period
Sustained organic growth throughout the period % 33,0 35 Impact of COVID-19 30 Return to normalized 24,0 25 Organic growth 21,0 21,0 organic growth of 6-7% 20 15 9 months 9 months Change Organic 9,0 9,1 In € millions 10 6,8 7,0 7,2 Post- 6,1 4,3 5,7 2021-2022 2022-2023 growth 5 COVID-19 0 -5 -0,1 -5
Slide 8: Homecare: return to organic growth excluding PPE
Homecare: return to organic growth excluding PPE 9-month 2022-2023 revenue: €163.2m (up 4.1%); (down 0.9% on an organic basis) E-commerce Communities €23.4M up 8.8% excluding PPE €72.5M • More dynamic levels of business in stores in the third Stores/ quarter Stores E-commerce • Contribution of Distr
Slide 9: Respiratory care: Excellent momentum and acceleration of growth in Q3
Respiratory care: Excellent momentum and acceleration of growth in Q3 Revenue for first 9 months of 2022-2023: • Excellent business momentum despite a 10% price cut in €120.5m France sleep apnea treatment effective September 1, 2021 (up 22.7%) (up 11.9% on an organic basis) €68.0m (up 14%) • Organic
Slide 10: NPSUC: excellent performance in the Nutrition-Perfusion-Diabetes segment
NPSUC: excellent performance in the Nutrition-Perfusion-Diabetes segment Revenue for first 9 months of 2022-2023: Diabetes €12.6M €96.5m (up 21.1%); (up 14.0% on an organic basis) €28.3M • Organic growth: 16.5% Stomatherapy Nutrition- Perfusion • Acceleration of organic growth during the period in b
Slide 11: Outlook
ey J}. <|> 5 & oS
Slide 12: Continue to outperform an already buoyant market
Maintaining strong organic growth Continue development of Homecare: Consolidate new Home Medical Assistance market share gains • Acceleration of growth in Respiratory • Consolidate business volumes with business (end of price cut) healthcare institutions in France, Belgium and Switzerland Continue t
Slide 13: Short and medium-term FCF drivers
Short and medium-term FCF drivers Improvement in CFO • increased business levels M&A financing, • • increased recurring operating margin good EBITDA to cash conversion within covenants Improvement in 2022-2023 Significant operating FCF and Reduced WCR improvement reduction in Group in FCF • inventor
Slide 14: Return to normal business momentum
Return to normal business momentum REVENUE Return to normal business Recurring >€510m operating €468m momentum margin > 8.3% €444m Organic growth across all segments Stable price Improved FCF environment 2020-2021 2021-2022 2022-2023 target Healthy working capital excluding new external and manageme
Slide 15: Shareholder information
Shareholder information Bastide vs CAC Mid Small over 10 years 45% 55% Concert: SIB Float + treasury (Bastide family) shares (0.4%) + BGV (Bastide family) 7,355,519 Number of shares €208m Capitalization at May 5, 2023 15
Slide 16: 9-month revenue 2022-2023
2022-2023 9-month revenue May 2023
Bastide Le Confort Medical — 9M 2022-2023 Earnings Presentation on 6ix